Novabay Pharmaceuticals Inc EV/EBIT
¿Qué es el EV/EBIT de Novabay Pharmaceuticals Inc?
El EV/EBIT de Novabay Pharmaceuticals Inc es N/A
¿Cuál es la definición de EV/EBIT?
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
EV/EBIT de compañías en Sector Health Care en NYSEMKT en comparadas con Novabay Pharmaceuticals Inc
¿Qué hace Novabay Pharmaceuticals Inc?
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Empresas con ev/ebit similar a Novabay Pharmaceuticals Inc
- ElectroCore Inc tiene EV/EBIT de N/A
- Ashok Alco-Chem tiene EV/EBIT de N/A
- Flow Beverage tiene EV/EBIT de N/A
- Northern Lights Resources tiene EV/EBIT de N/A
- Pure Gold Mining tiene EV/EBIT de N/A
- Unisys tiene EV/EBIT de N/A
- Novabay Pharmaceuticals Inc tiene EV/EBIT de N/A
- RMG Acquisition tiene EV/EBIT de N/A
- BSquare Corp tiene EV/EBIT de N/A
- Banjo & Matilda tiene EV/EBIT de N/A
- Exagen Inc tiene EV/EBIT de N/A
- Digital Turbine Inc tiene EV/EBIT de N/A
- Obalon Therapeutics Inc tiene EV/EBIT de N/A